11
Participants
Start Date
April 30, 2006
Primary Completion Date
May 31, 2008
Study Completion Date
September 30, 2008
Adalimumab
Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
The University of Chicago, Chicago
Collaborators (1)
Abbott
INDUSTRY
University of Chicago
OTHER